Chief Financial Officer

Nuvalent presents preliminary data for neladalkib from ALKOVE-1 Phase 1/2 trial

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025

Nuvalent resumed with a Buy at Stifel

Nuvalent Insider Sold Shares Worth $2,540,290, According to a Recent SEC Filing

Senior Director, Biostatistics - Oncology

Nuvalent, Inc. is an early-stage company focused on creating selective medicines for cancer patients. The Senior Director of Biostatistics will lead statistical activities for clinical studies, oversee CRO deliverables, and collaborate with internal and external teams to ensure high-quality statistical outputs.

Sign up with Google

Sign in with Google